SGMT · Sagimet Biosciences Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | — | $2M | — | |
| $34.99M | $39.05M | $38.44M | $19.78M | $24.92M | |
| $17.64M | $17.84M | $16.01M | $12.96M | $6.14M | |
| $52.63M | $56.89M | $54.45M | $32.74M | $31.06M | |
| -$52.63M | -$56.89M | -$54.45M | -$30.74M | -$31.06M | |
| — | — | — | -1537% | — | |
| $5.55M | $5.85M | $8.89M | $2.86M | $556K | |
| — | $0 | $0 | — | — | |
| -$47.08M | -$51.04M | -$45.57M | -$27.88M | -$30.5M | |
| — | — | — | -1393.8% | — | |
| -$47.23M | -$51.15M | -$45.37M | -$27.76M | -$30.58M | |
| USD/shares | -$1.29 | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| USD/shares | -$1.29 | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| shares | — | 32.35M | 31.35M | 10.46M | 184.62K |
| shares | — | 32.35M | 31.35M | 10.46M | 184.62K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 308 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2023 |
|---|---|
| Single Reportable Segment | $2,000,000 |